Welcome to our dedicated page for Quince SEC filings (Ticker: QNCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Quince Therapeutics’ disclosures can feel like navigating a clinical study—dense tables on bone-targeting pharmacokinetics, milestone payments, and risk factors for rare-disease trials. If you have ever asked, “Quince Therapeutics SEC filings explained simply,” this page solves that challenge.
Stock Titan’s AI converts every document into plain language bullet points, whether you are tracking a “Quince Therapeutics quarterly earnings report 10-Q filing” or monitoring “Quince Therapeutics insider trading Form 4 transactions.” Real-time alerts surface “Quince Therapeutics Form 4 insider transactions real-time,” highlight “Quince Therapeutics executive stock transactions Form 4,” and clarify each “Quince Therapeutics 8-K material events explained” filing within minutes of hitting EDGAR.
Use the platform to dive straight into what matters: R&D burn rates and pipeline updates in a “Quince Therapeutics annual report 10-K simplified,” revenue swings in a “Quince Therapeutics earnings report filing analysis,” or board pay packages inside a “Quince Therapeutics proxy statement executive compensation.” Our AI-powered summaries spotlight dosing data, orphan-drug designations, and collaboration royalties, while expert commentary shows how those details can affect cash runway and valuation. Spend less time decoding biotech jargon and more time acting on clear insights—understanding Quince Therapeutics SEC documents with AI has never been easier.
JPMorgan Chase Financial Company LLC, fully guaranteed by JPMorgan Chase & Co., is offering $13.698 million of Market-Linked Securities tied to the EURO STOXX 50® Index (SX5E) maturing on 30 June 2028. Each $1,000 note provides:
- 122% leveraged upside: at maturity investors receive principal plus 1.22× any positive index return.
- 25% fixed buffer: full principal is repaid if the index falls ≤25% from the 5,325.64 starting level (threshold 3,994.23).
- Downside exposure beyond buffer: losses match index declines below the threshold, capped at a 75% maximum loss; worst-case redemption is $250 per note.
- No coupons, no dividends, no listing; the securities are designed to be held to maturity and carry JPMorgan Financial/JPMorgan Chase & Co. credit risk.
Pricing & distribution: Issue price $1,000; selling commission $28.25 (2.825%); net proceeds $971.75. Wells Fargo Securities (agent) may share concessions with dealers and receive distribution expense fees. JPMS may pay additional $2.00 per note to selected dealers.
Estimated value set on the 27 June 2025 pricing date is $963.60, reflecting JPMorgan’s internal funding rate and hedging costs; therefore the offering premium over estimated value is roughly 3.78%. Secondary market bids will likely be below issue price and could be unavailable.
Key risks disclosed: potential loss of up to 75% of principal; issuer and guarantor credit risk; illiquidity; conflicts of interest in pricing and hedging; estimated value derived from internal models; uncertain U.S. tax treatment; exposure to non-U.S. equities without FX adjustment.
Target investors are those seeking equity-linked upside with partial downside buffer who can forgo income, tolerate credit and market risk, and hold to maturity.
Quince Therapeutics, Inc. (QNCX) – Form 4 insider transaction
Chief Business, Operations and Commercial Officer Brendan Hannah reported a purchase of company securities on 18 June 2025.
- Common shares acquired: 37,736 shares
- Purchase price: $1.20 per share
- Post-transaction direct ownership: 334,276 common shares
- Derivative securities acquired: 37,736 warrants with a $1.20 exercise price, expiring 18 June 2030; cost recorded at $0.125 per warrant
The filing indicates a straightforward insider purchase (Transaction Code “A”) rather than a sale or option exercise. No other changes to ownership structure or additional transactions were disclosed.
Materiality assessment: The transaction increases Hannah’s direct equity stake by approximately 11 % (37,736 ÷ 334,276 ≈ 11 %), but the absolute dollar value is relatively modest (≈ $45,000 for the shares, ≈ $4,700 for the warrants). There is no indication of broader strategic developments, earnings information, or company-level financial impact within this filing.
Quince Therapeutics (NASDAQ:QNCX) filed a Form 4 on June 28 2025 reporting that President Charles S. Ryan executed an insider purchase on June 18 2025.
Ryan bought 7,548 common shares at $1.20 each and simultaneously acquired 7,548 warrants with the same $1.20 exercise price, expiring 06/18/2030. His direct ownership rose to 130,009 common shares, an increase of roughly 5.8 %. No other material transactions or disclosures were included in the filing.
Quince Therapeutics (QNCX) filed a Form 4 disclosing that CEO, CMO and Director Dirk Thye increased his equity stake on 18 June 2025.
Thye acquired 150,944 common shares at $1.20 (Transaction Code A) and simultaneously received warrants for an additional 150,944 shares with the same $1.20 exercise price, expiring 18 June 2030. Following the transactions, his direct beneficial ownership rose to 994,885 common shares, an increase of roughly 15 %. The disclosed cash outlay for the common-share purchase is approximately $181 000; the warrants were priced at $0.125 each.
No shares were sold, and the filing does not indicate the use of a Rule 10b5-1 trading plan. These insider purchases may signal management confidence, though the dollar value is modest relative to typical market-moving thresholds.
FAQ
What is the current stock price of Quince (QNCX)?
What is the market cap of Quince (QNCX)?
What is the core focus of Quince Therapeutics Inc?
How does the bone-targeting drug platform work?
In which stage of development is Quince Therapeutics currently operating?
What types of therapeutic agents can be delivered using their platform?
How does Quince Therapeutics Inc differentiate itself from competitors?
What industry sectors does Quince Therapeutics primarily serve?
How does the company ensure patient safety with its targeted approach?
What are the main advantages of a targeted drug delivery system?
